Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated various compounds inhibiting testosterone 5alpha-reductase for potential treatment of benign prostatic hyperplasia, finding that heparin and progesterone demonstrated inhibitory effects under specific conditions.

This letter to the editor references a study on using dihydrotestosterone gel before hypospadias surgery but itself contains no new findings.

Dutasteride may help prevent prostate cancer, but more research is needed.

This study discovered that TTR is expressed in the human placenta as early as 6 weeks gestation, with increased levels in the first trimester potentially facilitating thyroid hormone delivery to the fetus.

This study found that androgen suppression therapy did not significantly reduce bladder cancer incidence overall but suggested finasteride use might lower the risk; recurrence-free survival was improved among AST users.

In this placebo-controlled study, finasteride significantly improved symptoms, reduced prostate size, and increased urine flow rate in patients with moderately symptomatic BPH over two years.

This study found that SRD5A2 expression is absent in one third of benign adult prostates and is associated with hypermethylation, suggesting potential personalization of treatment for prostatic diseases based on methylation status.

This study identified a mutation in the steroid-binding domain of the androgen receptor gene associated with complete androgen insensitivity syndrome, impairing male sexual development due to altered androgen receptor protein function.

This study observed that a longer anterior clitoral anogenital distance (AGDAC) is associated with polycystic ovary syndrome in adult Mediterranean women.

This study in humans and pigs found that finasteride metabolism is significantly influenced by CYP3A4, with induced metabolism decreasing and inhibited metabolism increasing plasma exposure of the drug.

This study found that sex steroid hormone receptors are largely maintained during the transformation of skin appendages to neoplasms, except for androgen and estrogen receptors in sweat and sebaceous gland tumors.

This study found that finasteride could enhance the stemness of dermal papilla cells, suggesting potential benefits for hair regeneration approaches.

This case study found that a 1.6cm ovarian Leydig cell tumor, causing hyperandrogenism in a postmenopausal woman, evaded detection on standard imaging techniques, underscoring the difficulty of diagnosing such tumors with imaging alone.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

In this study, researchers developed a carboxylated β-cyclodextrin formulation to enhance finasteride's physicochemical properties, achieving an encapsulation efficiency of about 85% and indicating potential for controlled drug release in therapeutic applications. Their findings suggest this inclusion complex could improve delivery of hydrophobic drugs like finasteride.

This study found that finasteride administration for more than one month before TURP surgery significantly reduces blood loss in patients with benign prostatic hyperplasia.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.

In this study, finasteride was found to significantly reduce DHT levels and affect spermatogenic markers in rats, while DA-9401 co-treatment indicated potential ameliorative effects.

This hypothesis paper suggests that sexual and cognitive dysfunctions reported by some men after using finasteride and dutasteride may stem from vascular and tissue changes in penile tissue triggering broader inflammatory effects.

This commentary notes that 5-alpha reductase inhibitors have successfully treated benign prostatic hyperplasia and androgenetic alopecia but reports no new findings.

This study found that exposure to finasteride impaired spermatogenesis in male Xenopus laevis by affecting sex-specific feedback mechanisms in the hypothalamus–pituitary–gonad axis.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

This study concluded that packaging tamsulosin and finasteride together for co-administration in patients with benign prostatic hyperplasia improves medication adherence compared to packaging each drug separately.

This study indicates that finasteride use may lower bladder cancer incidence, while androgen suppression therapy improves recurrence-free survival but not other survival outcomes in bladder cancer patients.